<DOC>
	<DOCNO>NCT03058224</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled exploratory trial investigate efficacy safety food supplement IGN-ES001 patient chronic widespread pain ( CWP ) without fibromyalgia ( FM ) .</brief_summary>
	<brief_title>Efficacy Safety IGN-ES001 Chronic Widespread Pain With Without Fibromyalgia</brief_title>
	<detailed_description>Patients perform five schedule on-site visit five phone call : - Screening visit , V1 ( Day -10 -7 ) , inform consent - Baseline visit , V2 ( Day 1 ) , randomization , treatment start - Phone call , V3 ( Day 4 ± 1 ) - Phone call , V4 ( Day 8 ± 3 ) - Phone call , V5 ( Day 15 ± 3 ) - On-site visit , V6 ( Day 22 ± 3 ) - Phone call , V7 ( Day 29 ± 3 ) - Phone call , V8 ( Day 36 ± 3 ) - On-site visit , V9 ( Day 43 + 3 ) , treatment end - Follow-up on-site visit , V10 ( Day 50 + 7 , 7 + 7 day EDV ) . In addition , patient may ask return trial site schedule visit assessment safety data ( unscheduled visit ) . The maximum duration treatment individual patient 46 day ( include allow visit window deviation ) . The maximum duration trial participation individual patient 67 day .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>1 . Male female outpatient ≥ 18 year ≤ 70 year age . 2 . Patient willing able ( e.g . mental physical condition ) participate aspect trial , include use investigational product , subjective completion diary questionnaires , attend schedule visit , complete telephone interview , compliant protocol requirement evidence provide sign writteninformed consent . 3 . History chronic widespread pain ( least three month prior visit V1 ( screen ) ) . 4 . . ) For FM patient : Widespread Pain Index ( WPI ) ≥ 7 Symptom Severity ( SS ) ≥ 5 WPI 36 SS ≥ 9 ( original preliminary fibromyalgia criterion American College Rheumatology ( ACR ) 2010 ) . b . ) For nonFM CWP patient : WPI ≥ 36 SS ≥ 58 ( modify preliminary fibromyalgia criterion ACR 2010 ) . 5 . Use prior concomitant medications/ therapy ( exclude , see exclusion criterion 6 7 ) , nonpharmacological therapy lifestyle habit ( e.g . diet change , Ramadan participation , etc . ) could influence efficacy assessment must stable least 30 day prior visit V1 ( screen ) anticipate stable regimen throughout trial visit V9 . 6 . Patient negative urine test screen visit V1 follow drug abuse : 1 . Amphetamine 2 . Cocaine 3 . Metamphetamine 4 . Morphine 5 . Tetrahydrocannabinol 7 . Female patient surgically sterile ( i.e . bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , least two year postmenopausal , childbearing potential , sexually abstinent agrees practice adequate contraceptive measure ( hormonal contraceptive , intrauterine device , doublebarrier method ) . 8 . Patient must complete least 6 screen phase diary page satisfactorily within past 7 day visit V2 . 9 . Median pain NRS must ≥ 4 least 1 6 pain quality ≥ 4 overall pain assessment . The median calculate last 7 day visit V2 ( baseline ) serve baseline value . If inclusion criterion fulfil ( none exclusion criterion ) , patient randomize visit V2 continue trial . Otherwise patient exclude trial participation . 1 . Patients without basic stable CWP therapy start least 30 day V1 ( screen ) i.e . treatmentnaive patient , first diagnosis . 2 . Known allergy intolerance egg egg constituent . 3 . History currently active malignancy except malignancy successfully treat recurrence within 5 year screen visit V1 . 4 . Known , uncontrolled endocrine disorder , hypothyroidism ( TSH free T4 ) , diabetes mellitus ( HbA1c ) . 5 . Known severe hepatic , renal , respiratory , hematologic , neurologic , infectious , immunologic disease , unstable cardiovascular disease , medical psychiatric condition , judgment investigator , would make patient inappropriate participation trial . 6 . Immune response modulate medication/ therapy e.g . systemic corticosteroid , antibody IP ( investigational product ) period start 90 day visit V1 ( screen ) . 7. WHO stepII stepIII opioids ( except occasional use codeine cough medication ) period start 60 day visit V1 ( screen ) . 8 . Intractable vomit likely significantly influence gastrointestinal ( GI ) investigational product presence . 9 . Surgery within 60 day visit V1 ( screen ) anticipate schedule next nine week visit V1 ( screen ) . 10 . Vaccination period start 30 day prior visit V1 ( screen ) . 11 . Known liver disease evidence impair hepatic function ( total bilirubin , aspartate aminotransferase [ ASAT ] , alanine transaminase [ ALAT ] , gammaglutamyltransferase [ GGT ] , alkaline phosphatase [ AP ] &gt; 3 time upper limit normal ) . 12 . Known kidney disease evidence impair renal function , i.e . estimate glomerular filtration rate ( eGFR ) base serum creatinine &lt; 60 mL/min calculate Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) formula . 13 . Pregnancy breastfeed . 14 . Known severe psychiatric illness ( e.g . schizophrenia , major depression , anxiety disorder , obsessive compulsive disorder , panic disorder , social phobia , posttraumatic stress ) personality disorder ( e.g . borderline personality ) . Obvious suicide risk . 15 . Current and/ history know suspected drug substance abuse include alcohol abuse within five year visit V1 ( screen ) state patient and/ withdrawal symptom . 16 . Previous enrolment trial , participation study involve investigational product , simultaneously within six month prior screen trial ( visit V1 ) . 17 . Persons committed institution virtue order issue either judicial authority . 18 . Employee investigator trial site , direct involvement propose trial study direction investigator trial site , well family member employee investigator . 19 . Patients unable unwilling include yoghurt ayran daily diet . 20 . Severe diarrhea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pain , Symptom Severity</keyword>
	<keyword>Immunoglobulin IgY</keyword>
	<keyword>Fibromyalgia</keyword>
	<keyword>Widespread Pain Index</keyword>
	<keyword>Eggyolk</keyword>
	<keyword>FIQ-R</keyword>
	<keyword>SF-36v2TM</keyword>
	<keyword>MOS-SS</keyword>
	<keyword>FSS</keyword>
	<keyword>PGIC</keyword>
	<keyword>Quality life</keyword>
</DOC>